ARTV
NASDAQ · Biotechnology
Artiva Biotherapeutics Inc
$6.69
+0.25 (+3.88%)
Financial Highlights (FY 2026)
Revenue
567.1K
Net Income
-147,662,558
Gross Margin
—
Profit Margin
-26,045.0%
Rev Growth
-50.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 30.8% | 30.8% |
| Operating Margin | -26,805.6% | -24,125.0% | -17.3% | -16.8% |
| Profit Margin | -26,045.0% | -24,742.8% | -16.8% | -19.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 567.1K | 1.13M | 14.43M | 14.50M |
| Gross Profit | — | — | 4.44M | 4.46M |
| Operating Income | -152,017,392 | -273,357,947 | -2,502,424 | -2,443,580 |
| Net Income | -147,662,558 | -265,527,077 | -2,421,627 | -2,767,986 |
| Gross Margin | — | — | 30.8% | 30.8% |
| Operating Margin | -26,805.6% | -24,125.0% | -17.3% | -16.8% |
| Profit Margin | -26,045.0% | -24,742.8% | -16.8% | -19.1% |
| Rev Growth | -50.0% | -50.0% | +14.0% | +5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 63.3K | 63.3K | 16.72M | 14.95M |
| Total Equity | 70.38M | 70.38M | 53.96M | 56.37M |
| D/E Ratio | 0.00 | 0.00 | 0.31 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -154,251,730 | -292,785,501 | -2,990,686 | -3,421,626 |
| Free Cash Flow | — | — | -1,604,262 | -1,971,320 |